The global cancer vaccines market is segmented based on technology, indication, type end use, and region. Based on technology, it is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, and viral vector & DNA cancer vaccines. Based on indication, it is bifurcated into cervical cancer, prostate cancer, and others. On the basis of end use, it is classified into pediatric vaccines and adult vaccines. Based on type, the market is divided into therapeutic cancer vaccines and preventive cancer vaccines.
Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the highest market share in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the increase in prevalence of cervical cancers, rise in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements in vaccine administration. However, Asia-Pacific is expected to witness maximum growth potential, due to the improvement in healthcare facilities, high disposable income, and rapid development of economic conditions.
The study provides an in-depth analysis of the global cancer vaccines market with current trends and future estimations to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.
Comprehensive quantitative analysis of the industry from 2016 to 2023 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry to understand the type of products and technologies used globally.
Key market players and their strategies are provided to understand the competitive outlook of the market.
KEY MARKET SEGMENTS
Dendritic Cells (DC) Cancer Vaccines
Recombinant Cancer Vaccines
Antigen/Adjuvant Cancer Vaccines
Whole Cell Cancer Vaccines
Viral Vector & DNA Cancer Vaccines
Preventive Cancer Vaccines
Therapeutic Cancer Vaccines
BY END USE
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
KEY PLAYERS PROFILED
AstraZeneca PLC. (Medimmune, LLC.)
Merck & Co., Inc.
Aduro BioTech Inc.
Astellas Pharma Inc.
Serum Institute of India Pvt. Ltd.
The other players in the value chain include (profiles not included in the report)
VBI Vaccines Inc.
Dynavax Technologies Corporation
Immunomic Therapeutics, Inc.
Gamma Vaccines Pty Limited
Sinovac Biotech Ltd.
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. PORTERS FIVE FORCES ANALYSIS
3.4. REGULATORY FRAMEWORK
3.5. MARKET SHARE ANALYSIS, 2016
3.6. MARKET DYNAMICS
22.214.171.124. Rising prevalence of human papilloma virus (HPV) infections, causing cancers
126.96.36.199. Increasing administration of prophylactic cancer vaccines
188.8.131.52. Rising investments and government funding in the development of cancer vaccines
184.108.40.206. Launch and approval of new cancer vaccines in the market
220.127.116.11. High cost for development of cancer vaccines due to the need of frequent upgradation in manufacturing technology
18.104.22.168. Longer timelines required for manufacturing a single vaccine
22.214.171.124. Increasing transition from prophylactic to therapeutic cancer vaccines
126.96.36.199. High growth prospects in emerging markets
CHAPTER 4 CANCER VACCINES MARKET, BY TECHNOLOGY
4.1.1. Market size and forecast
4.2. DENDRITIC CELLS CANCER VACCINES
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.3. RECOMBINANT CANCER VACCINES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. ANTIGEN/ADJUVANT CANCER VACCINES
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.5. WHOLE CELL CANCER VACCINES
4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.6. VIRAL VECTOR AND DNA CANCER VACCINES
4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast
CHAPTER 5 CANCER VACCINES MARKET, BY TYPE
5.1.1. Market size and forecast
5.2. PREVENTIVE CANCER VACCINES
5.2.1. Market size and forecast
5.3. THERAPEUTIC CANCER VACCINES
5.3.1. Market size and forecast
CHAPTER 6 CANCER VACCINES, BY INDICATION
6.1.1. Market size and forecast
6.2. CERVICAL CANCER
6.2.1. Market size and forecast
6.3. PROSTATE CANCER
6.3.1. Market size and forecast
6.4. OTHER INDICATIONS
6.4.1. Market size and forecast
CHAPTER 7 CANCER VACCINES MARKET, BY END USE
7.1.1. Market size and forecast
7.2.1. Market size and forecast
7.3.1. Market size and forecast
CHAPTER 8 CANCER VACCINES MARKET, BY GEOGRAPHY
8.1.1. Market size and forecast
8.2. NORTH AMERICA
8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast
188.8.131.52. U.S. market size and forecast
184.108.40.206. Mexico market size and forecast
220.127.116.11. Canada market size and forecast
8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast
18.104.22.168. UK market size and forecast
22.214.171.124. France market size and forecast
126.96.36.199. Germany market size and forecast
188.8.131.52. Italy market size and forecast
184.108.40.206. Spain market size and forecast
220.127.116.11. Rest of Europe market size and forecast
8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast
18.104.22.168. Japan market size and forecast
22.214.171.124. China market size and forecast
126.96.36.199. India market size and forecast
188.8.131.52. Australia market size and forecast
184.108.40.206. Rest of Asia-Pacific market size and forecast
8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast
220.127.116.11. Brazil market size and forecast
18.104.22.168. Argentina market size and forecast
22.214.171.124. Turkey market size and forecast
126.96.36.199. South Africa market size and forecast
188.8.131.52. Rest of LAMEA market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1. ASTRAZENECA PLC. (MEDIMMUNE, LLC.)
9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Business performance
9.1.5. Key strategic moves and developments
9.2. GLAXOSMITHKLINE PLC.
9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Operating business segments
9.2.4. Business performance
9.2.5. Key strategic moves and developments
9.3. MERCK & CO., INC.
9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Business performance
9.3.5. Key strategic moves and developments
9.4. SANOFI PASTEUR
9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Business performance
9.4.5. Key strategic moves and developments
9.5. ADURO BIOTECH INC.
9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Business performance
9.5.5. Key strategic moves and developments
9.6. SANPOWER GROUP CO., LTD.
9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Operating business segments
9.6.4. Business performance
9.6.5. Key strategic moves and developments
9.7. ASTELLAS PHARMA INC.
9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Business performance
9.7.5. Key strategic moves and developments
9.8. CSL LIMITED
9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Business performance
9.8.5. Key strategic moves and developments
9.9. PFIZER INC.
9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Business performance
9.9.5. Key strategic moves and developments
9.10. SERUM INSTITUTE OF INDIA PVT. LTD.
9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Operating business segments
9.10.4. Business performance
9.10.5. Key strategic moves and developments
Vaccines include antigenic components, which strengthens an individuals immune system by developing adaptive immunity to prevent morbidity from infections. Cancer vaccine is a type of immunotherapy that boost the bodys natural defenses by stimulating the immune system to recognize and cure cancerous cells.
The global market is driven by rise in prevalence of HPV infections and related cancer, increase in administration of prophylactic cancer vaccines, surge in investments & findings in the development of cancer vaccines, and launch of novel cancer vaccines in the market. However, longer timelines required for manufacturing a single vaccine restrain the development of new vaccines; thereby, hampering the market growth. In addition, high monetary inputs for the development of cancer vaccines decrease their adoption in the market; thereby, hampering the market growth.
The cervical cancer segment accounted for maximum market revenue in 2016, and is anticipated to maintain its dominant position during the forecast period, owing to the increase in number of people suffering from human papilloma virus (HPV) infections, which causes approximately 70% of cervical cancers globally. In addition, high prevalence of cervical, prostate, lungs, and breast cancer among adults propel the market growth. However, prostate cancer is growing at the highest CAGR of 18.6% from 2017 to 2023, owing to the increase in demand for Provenge (prostate cancer vaccine) along with the increase in number of prostate cancer vaccines in the pipeline.
The recombinant cancer vaccines segment dominated the global market in 2016, and is expected to maintain its dominance throughout the forecast period. This is attributed to the large number of approved cancer vaccines developed using recombinant technology such as Cervarix, Gardasil, and Recombivax HB. The therapeutic cancer vaccines segment is anticipated to register the highest growth rate during the forecast period, owing to the increase in transition from prophylactic cancer vaccines to therapeutic cancer vaccines.
The adult cancer vaccine segment dominated the end use market, accounting for about fifth-eighths share of the global market in 2016, due to the increase in incidence of HPV infections, breast cancers, and prostate cancers among adults. Moreover, active government participation for provision of vaccination to all children has augmented the market growth.
Key Findings of the Cancer Vaccines Market:
The dendritic cells cancer vaccines segment is anticipated to grow at the highest rate during the forecast period.
The preventive cancer vaccines segment dominated the global market, accounting for five-ninths share of the global market in 2016.
North America dominated the global market, accounting for the maximum share of overall market in 2016, and is expected to continue this trend throughout the forecast period.
Asia-Pacific is exhibited to grow at a CAGR of 19.6% during the forecast period, owing to the high demand for vaccination in densely populated countries, such as India and China.
The cervical cancer segment generated the highest revenue in 2016, and is expected to continue its dominance in the near future.
The pediatric vaccines segment is expected to exhibit high growth rate during forecast period, owing to the increase in demand for preventive cancer vaccines.
Asia-Pacific witnessed the highest growth rate for cancer vaccines in 2016, and is expected to continue this trend throughout the forecast period. This is attributed to large population base, rise in incidence of HPV infection related cancers & other cancer cases, healthcare infrastructural development, and huge market potential. Moreover, the introduction of novel preventive, therapeutic, and adult cancer vaccines in the market along with the increasing focus by key players in the emerging markets has fueled the growth of the industry.
The key players operating in the vaccines market have adopted product launch as their key developmental strategy and focus on launching innovative products to cater to the consumer requirements and strengthen their market shares. The major companies profiled in the report include Astrazeneca Plc. (Medimmune, LLC.), Glaxosmithkline Plc., Merck & Co., Inc., Sanofi Pasteur, Aduro BioTech Inc., Sanpower Group, Astellas Pharma Inc., CSL Limited, Pfizer Inc., and Serum Institute of India Pvt. Ltd.
The other key players in the value chain include Gritstone Oncology, PaxVax Corporation., Bavarian Nordic, Bharat Biotech., VBI Vaccines Inc., Novavax, Inc., Dynavax Technologies Corporation, Immunomic Therapeutics, Inc., Gamma Vaccines Pty Limited, Sinovac Biotech Ltd., Galena Biopharma, Emergent Biosolutions, Prokarium, and ImmunoBiology Ltd.
- AstraZeneca PLC. (Medimmune, LLC.)
- Glaxosmithkline Plc.
- Merck & Co., Inc.
- Sanofi Pasteur
- Aduro BioTech Inc.
- Astellas Pharma Inc.
- CSL Limited
- Pfizer Inc.
- Sanpower Group
- Serum Institute of India Pvt. Ltd.